Sumitomo Pharma’s stock price dropped by as much as 14.4% on Friday after Japan approved its regenerative therapy, which is based on technology developed by a Nobel Prize winner. The approval was given conditionally, with the company required to collect more data over the next seven years. Analysts think this might be the reason for the short-term decline in stock price, as investors take profits from the news of the smooth approval process.
Source: https://www.bloomberg.com/news/articles/2026-02-20/sumitomo-pharma-shares-drop-after-stem-therapy-backing